EICHOR
● Active Not Recruiting
Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment
Condition: Urinary Bladder Neoplasms · Immunotherapy · Sponsor: Fudan University
About this study
This study will evaluate the safety and efficacy of bladder intravesical Camrelizumab in patients with high-risk non-muscle-invasive bladder cancer who failed BCG therapy.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (4)
| Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | — |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | — |
| Shanghai Tenth People's Hospital,Shanghai Tong Ji University School of Medicine | Shanghai, Shanghai Municipality, China | — |
| Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04706598